Pfizer pharmaceuticals, by way of an independent research grant, is funding a 3 year trial into the effectiveness of traditional non-steroidal anti-inflammatory drugs (NSAIDS), such as ibuprofen and diclofenac, and a newer one called celecoxib. Pfizer, which markets celecoxib under the brand name Celebrex, is spending £26 million ($52.5 million) on the study.
The Standard Care vs. [...]






















